Arkstone, a trailblazer in machine learning (ML) and artificial intelligence (AI)-powered clinical decision support for infectious disease and antimicrobial stewardship, has been acquired by ARCHIMED, a global private equity firm with deep specialization in the healthcare sector.
This strategic acquisition marks a significant milestone in Arkstone’s journey, setting the stage for accelerated international expansion, enhanced research and development, and wider deployment of its precision-guided technologies. With the backing of ARCHIMED’s robust capital resources, healthcare domain expertise, and global footprint, Arkstone is well-positioned to expand its impact in the critical fight against antimicrobial resistance (AMR)—a growing global health crisis.
“Arkstone’s OneChoice Report is redefining infectious disease management. Our partnership will enable Arkstone to reach more markets, accelerate product innovation, and ultimately save lives by reducing the misuse of antibiotics,” said Igor Petricca, Partner at ARCHIMED. “This deal offers an additional dimension, as Clinical Decision Support software (CDS) and infectious disease are at the crossroads of hot subsectors of our Healthcare IT and Diagnostics franchises.”
At the heart of Arkstone’s innovation is its flagship solution, the OneChoice Report. Utilizing a human-in-the-loop approach that integrates machine learning and AI, the platform analyzes lab data and patient-specific information to deliver tailored infectious disease treatment recommendations. This patient-centric guidance is delivered to healthcare providers at the precise moment lab results become available—helping clinicians make more accurate, timely decisions. Already deployed by laboratories across the U.S. and internationally, the solution is reshaping how infectious diseases are diagnosed and treated.
Also Read: ACTO Unveils CXZone: AI Roleplay Tool for Pharma Reps
“ARCHIMED’s acquisition of Arkstone supercharges our mission and opens new horizons for innovation and global reach,” said Ari Frenkel, MD, MPH, Chief Science Officer and Co-Founder of Arkstone. “This partnership ensures we have the resources, network, and strategic guidance to deliver our vision globally. Together, we’ll expand access to the tools clinicians need to combat antimicrobial resistance and prescribe responsibly.”
Arkstone will maintain operations under its current leadership team post-acquisition. The company’s focus moving forward will include scaling its operations, enhancing product capabilities, and entering new markets.
Dave Gross, Chief Technology Officer and Co-Founder of Arkstone, commented, “This partnership marks a transformative milestone for Arkstone. ARCHIMED‘s deep expertise and global presence will significantly enhance our ability to innovate rapidly and bring life-saving antimicrobial stewardship solutions to a broader global audience. We’re thrilled to begin this exciting new chapter.”
The acquisition highlights the increasing importance of clinical decision support technologies and responsible antibiotic use. It positions Arkstone at the forefront of global efforts to improve infectious disease management through the integration of advanced AI tools.
“This acquisition is a powerful affirmation of the deep trust we’ve earned with our partners and the world-class support our team delivers,” said Sol Levi, Chief Customer Officer and Co-Founder at Arkstone. “This is an opportunity to bring our personalized approach to even more partners, innovate faster, and deepen the collaborative relationships that have always defined Arkstone’s success.”
